The prognostic value and immune correlation of IL18 expression and promoter methylation in renal cell carcinoma

Clinical Epigenetics

Research

Qian Long¹  Haohui Sun²  Enni Chen²  Xiaodi Li²  Wuguo Deng²  Liru He²  Wancui Zhu²  Pei Dong²  Miao Chen²  Xiaonan Wang³  Hailin Xu⁴  Weizhao Li⁵ 

[1] Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China;Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China;Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China;Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China;The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China;The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China;

关键词: Renal cell carcinoma (RCC);    IL18;    DNA methylation;    Epigenetic biomarker;    Tumor immune cell infiltration;   

DOI  :  10.1186/s13148-023-01426-8

 received in 2022-07-20, accepted in 2023-01-12,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundRenal cell carcinoma (RCC) is not sensitive to immunotherapy and has poor prognosis. DNA methylation regulates gene expression, and its abnormal changes are related to many human diseases. Recently, DNA methylation has been found to participate in immune infiltration in various cancers. However, its pattern in RCC remains poorly understood.ResultsWe found that IL18 was significantly over-expressed in RCC tumor tissues compared to normal adjacent tissues The IL18 promoter region was hypomethylated, which was strongly correlated with elevated IL18 mRNA expression, and predicted advanced clinicopathological characteristics and shorter overall survival. Furthermore, we found that IL18 promoter methylation was significantly related to the down-regulation of immune checkpoint molecules and increase of CD8 + T cell infiltration in RCC tumor tissues.ConclusionsWe have identified the important role of IL18 promoter methylation and expression, which are associated with clinicopathological characteristics, overall survival, immune cell infiltration and expression of immune checkpoint molecules in RCC. We present the rationale for IL18 promoter methylation as a molecular biomarker for predicting the response of RCC to immune checkpoint inhibitors.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 28

41116_2022_35_Article_IEq504.gif

Fig. 23

41116_2022_35_Article_IEq481.gif

Fig. 1

41116_2022_35_Article_IEq469.gif

41116_2022_35_Article_IEq439.gif

12888_2022_4443_Article_IEq8.gif

12888_2022_4443_Article_IEq6.gif

41116_2022_35_Article_IEq397.gif